Print

Cancer Research Consortium of West Michigan

Lung Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.

Provided drugs are underlined

For more information, call the CRCWM Main office at 616.391.1230 or 800.336.5079

Narrow List by Age:

Lung

Cancer Type: Lung Cancer
Research Base: Wake Forest
Protocol: WF- 20817CD

Implementation of Smoking Cessation Services (OaSiS)

Cancer Type: Lung Cancer
Research Base: Alliance
Protocol: Alliance A221504

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY OF AN ORAL, SELECTIVE PERIPHERAL OPIOID RECEPTOR ANTAGONIST IN ADVANCED NON-SMALL CELL LUNG CANCER (ADENOCARCINOMA)

Cancer Type: Advanced NSCLC
Research Base: ECOG-ACRIN
Protocol: EA5162

Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR

Cancer Type: NSCLC
Research Base: SWOG
Protocol: LUNG MAP

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer

Cancer Type: NSCLC
Research Base: SWOG
Protocol: SWOG S1900A

A PHASE II STUDY OF RUCAPARIB IN PATIENTS WITH GENOMIC LOH HIGH AND/OR DELETERIOUS BRCA1/2 MUTATION STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (Lung-MAP SUB-STUDY)

Cancer Type: Non-Small Cell Lung Cancer (NSCLC)
Research Base: ECOG-ACRIN
Protocol: EA5163

A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis

Cancer Type: Recurrent Non-Small Cell Lung Cancer
Research Base: SWOG
Protocol: SWOG S1800A

A Phase II Study of Ramucirumab Plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

Cancer Type: Limited Stage Small Cell Lung Cancer
Research Base: NRG
Protocol: NRG LU005

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

Cancer Type: Lung Cancer
Research Base: SWOG
Protocol: SWOG S1400F

A Phase II Study of MEDI4736 (Durvalumab) plus Tremelimumab as Therapy for Patients with Previously Treated ANTI-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-MAP Non-Match Sub-Study)

Cancer Type: METASTATIC NON-SMALL CELL LUNG CANCER
Research Base: NRG
Protocol: NRG LU002

MAINTENANCE SYSTEMIC THERAPY VERSUS CONSOLIDATIVE STEREOTACTIC BODY RADIATION THERAPY (SBRT) PLUS MAINTENANCE SYSTEMIC THERAPY FOR LIMITED METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE II/III TRIAL

Cancer Type: Non-Small Cell Lung
Research Base: Alliance
Protocol: Alliance A151216

Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Sub-Studies to ALCHEMIST: A081105,  E4512 and EA5142

Cancer Type: Non-Small Cell Lung
Research Base: CTSU
Protocol: ECOG E4512

ECOG E4512: Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib/Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Cancer Type: Non-Small Cell Lung
Research Base: Alliance
Protocol: Alliance A081105

Alliance A081105: Randomized Double Blind study of Erlotinib/Placebo in patients with completely resected epidermal growth factor recepter (EGFR) mutant non-small cell lung cancer (NSCLC)

Cancer Type: SCLC
Research Base: NRG
Protocol: NRG CC003

NRG CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer

Cancer Type: Limited Small Cell Lung Cancer
Research Base: Alliance
Protocol: CALGB 30610
 

CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide